

Ruth Dobson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3829050/publications.pdf>

Version: 2024-02-01

127
papers

5,379
citations

136740

32
h-index

91712

69
g-index

150
all docs

150
docs citations

150
times ranked

6691
citing authors

#	ARTICLE	IF	CITATIONS
1	Multiple sclerosis – a review. European Journal of Neurology, 2019, 26, 27-40.	1.7	1,057
2	Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurology, The, 2010, 9, 727-739.	4.9	459
3	Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases. PLoS ONE, 2013, 8, e75091.	1.1	375
4	Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 909-914.	0.9	293
5	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Multiple Sclerosis Journal, 2015, 21, 1013-1024.	1.4	249
6	Smoking and Multiple Sclerosis: An Updated Meta-Analysis. PLoS ONE, 2011, 6, e16149.	1.1	220
7	Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 273-279.	0.9	144
8	The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis. Multiple Sclerosis Journal, 2013, 19, 162-166.	1.4	139
9	The month of birth effect in multiple sclerosis: systematic review, meta-analysis and effect of latitude. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 427-432.	0.9	132
10	<scp>COVID</scp>â€19 Vaccine Response in People with Multiple Sclerosis. Annals of Neurology, 2022, 91, 89-100.	2.8	119
11	UK consensus on pregnancy in multiple sclerosis: –Association of British Neurologistsâ€™ guidelines. Practical Neurology, 2019, 19, 106-114.	0.5	118
12	Bone health in Parkinson's disease: a systematic review and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1159-1166.	0.9	114
13	Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-309690.	0.9	90
14	Epidemiology of Epstein-Barr virus infection and infectious mononucleosis in the United Kingdom. BMC Public Health, 2020, 20, 912.	1.2	90
15	The effect of vitamin D-related interventions on multiple sclerosis relapses: a meta-analysis. Multiple Sclerosis Journal, 2013, 19, 1571-1579.	1.4	84
16	BMI and low vitamin D are causal factors for multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	67
17	Assessing treatment response to interferon-Î². Neurology, 2014, 82, 248-254.	1.5	61
18	Parkinsonâ€™s disease determinants, prediction and geneâ€™environment interactions in the UK Biobank. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1046-1054.	0.9	59

#	ARTICLE	IF	CITATIONS
19	Sex effects across the lifespan in women with multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642093616.	1.5	58
20	Autoimmune disease in people with multiple sclerosis and their relatives: a systematic review and meta-analysis. <i>Journal of Neurology</i> , 2013, 260, 1272-1285.	1.8	57
21	Systematic review and meta-analysis of the association between Epstein-Barr virus, multiple sclerosis and other risk factors. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1281-1297.	1.4	55
22	A comparative analysis of Patient-Reported Expanded Disability Status Scale tools. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1349-1358.	1.4	54
23	COVID-19 in people with multiple sclerosis: A global data sharing initiative. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1157-1162.	1.4	50
24	Meta-Analysis of the Relationship between Multiple Sclerosis and Migraine. <i>PLoS ONE</i> , 2012, 7, e45295.	1.1	49
25	The effects of intrathecal rituximab on biomarkers in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 6, 49-53.	0.9	47
26	Vitamin D supplementation. <i>Practical Neurology</i> , 2018, 18, 35-42.	0.5	43
27	Treatment of Women with Multiple Sclerosis Planning Pregnancy. <i>Current Treatment Options in Neurology</i> , 2021, 23, 11.	0.7	43
28	Bone health and multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1522-1528.	1.4	40
29	Protecting people with multiple sclerosis through vaccination. <i>Practical Neurology</i> , 2020, 20, 435.1-445.	0.5	40
30	Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 107-109.	0.9	38
31	Lower Lymphocyte Count is Associated With Increased Risk of Parkinson's Disease. <i>Annals of Neurology</i> , 2021, 89, 803-812.	2.8	38
32	The effect of gender in clinically isolated syndrome (CIS): a meta-analysis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 600-604.	1.4	37
33	Validating a novel web-based method to capture disease progression outcomes in multiple sclerosis. <i>Journal of Neurology</i> , 2013, 260, 2505-2510.	1.8	35
34	COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 52, 102939.	0.9	34
35	Epstein-Barr-negative MS: a true phenomenon?. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e318.	3.1	33
36	Change practice now! Using atraumatic needles to prevent post lumbar puncture headache. <i>European Journal of Neurology</i> , 2014, 21, 305-311.	1.7	32

#	ARTICLE	IF	CITATIONS
37	Gene-Environment Interactions in Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	32
38	Assessment of Risk Factors and Early Presentations of Parkinson Disease in Primary Care in a Diverse UK Population. <i>JAMA Neurology</i> , 2022, 79, 359.	4.5	25
39	Bone health in chronic neurological diseases: a focus on multiple sclerosis and parkinsonian syndromes. <i>Practical Neurology</i> , 2013, 13, 70-79.	0.5	24
40	Change in pregnancy-associated multiple sclerosis relapse rates over time: a meta-analysis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102241.	0.9	21
41	Ethnic and Socioeconomic Associations with Multiple Sclerosis Risk. <i>Annals of Neurology</i> , 2020, 87, 599-608.	2.8	21
42	Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 52, 103028.	0.9	20
43	Viral pathophysiology of multiple sclerosis: A role for Epstein-Barr virus infection?. <i>Pathophysiology</i> , 2011, 18, 13-20.	1.0	19
44	Blood glucose monitoring using microwave cavity perturbation. <i>Electronics Letters</i> , 2012, 48, 905.	0.5	19
45	A service development study of the assessment and management of fracture risk in Parkinson's disease. <i>Journal of Neurology</i> , 2014, 261, 1153-1159.	1.8	19
46	The Influence of Socioeconomic Deprivation on Dementia Mortality, Age at Death, and Quality of Diagnosis: A Nationwide Death Records Study in England and Wales 2001-2017. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 321-328.	1.2	19
47	CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103448.	0.9	19
48	Use of disease-modifying drugs during pregnancy and breastfeeding. <i>Current Opinion in Neurology</i> , 2021, 34, 303-311.	1.8	18
49	Mental health of people with multiple sclerosis during the COVID-19 outbreak: A prospective cohort and cross-sectional case-control study of the UK MS Register. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1060-1071.	1.4	18
50	Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 64, 103937.	0.9	18
51	Cerebrospinal fluid and urinary biomarkers in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2013, 128, n/a-n/a.	1.0	17
52	Atraumatic needles for lumbar puncture: why haven't neurologists changed?. <i>Practical Neurology</i> , 2016, 16, 18-22.	0.5	17
53	Genomic Regions Associated with Multiple Sclerosis Are Active in B Cells. <i>PLoS ONE</i> , 2012, 7, e32281.	1.1	16
54	Summary-data-based Mendelian randomization prioritizes potential druggable targets for multiple sclerosis. <i>Brain Communications</i> , 2020, 2, fcaa119.	1.5	16

#	ARTICLE	IF	CITATIONS
55	Demyelinating Events Following Initiation of Anti-TNF \pm Therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid Arthritis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	16
56	Early predictors of disability of paediatric-onset AQP4-IgG-seropositive neuromyelitis optica spectrum disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 101-111.	0.9	16
57	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1424-1456.	1.4	16
58	The Refinement of Genetic Predictors of Multiple Sclerosis. <i>PLoS ONE</i> , 2014, 9, e96578.	1.1	15
59	Multiple sclerosis therapy and Epstein-Barr virus antibody titres. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 372-374.	0.9	15
60	Big data, machine learning and artificial intelligence: a neurologist's guide. <i>Practical Neurology</i> , 2020, , practneurol-2020-002688.	0.5	14
61	Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?. <i>Clinical and Experimental Immunology</i> , 2022, 207, 263-271.	1.1	14
62	Melanoma associated retinopathy and how to understand the electroretinogram. <i>Practical Neurology</i> , 2011, 11, 234-239.	0.5	13
63	Risk Factors, Epidemiology and Treatment Strategies for Metabolic Bone Disease in Patients with Neurological Disease. <i>Current Osteoporosis Reports</i> , 2016, 14, 199-210.	1.5	13
64	Visibility and representation of women in multiple sclerosis research. <i>Neurology</i> , 2019, 92, 713-719.	1.5	13
65	Dementia risk in a diverse population: A single-region nested case-control study in the East End of London. <i>Lancet Regional Health - Europe, The</i> , 2022, 15, 100321.	3.0	13
66	Anti-CD20 therapies in pregnancy and breast feeding: a review and ABN guidelines. <i>Practical Neurology</i> , 2023, 23, 6-14.	0.5	13
67	The difficulties with vitamin B ₁₂ . <i>Practical Neurology</i> , 2016, 16, 308-311.	0.5	12
68	A Risk Score for Predicting Multiple Sclerosis. <i>PLoS ONE</i> , 2016, 11, e0164992.	1.1	11
69	Assessing fracture risk in people with MS: a service development study comparing three fracture risk scoring systems. <i>BMJ Open</i> , 2013, 3, e002508.	0.8	10
70	MS, pregnancy and COVID-19. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1137-1146.	1.4	10
71	Current review and next steps for artificial intelligence in multiple sclerosis risk research. <i>Computers in Biology and Medicine</i> , 2021, 132, 104337.	3.9	10
72	Estimated and projected burden of multiple sclerosis attributable to smoking and childhood and adolescent high body-mass index: a comparative risk assessment. <i>International Journal of Epidemiology</i> , 2021, 49, 2051-2057.	0.9	9

#	ARTICLE	IF	CITATIONS
73	Increased urinary free immunoglobulin light chain excretion in patients with multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2010, 220, 99-103.	1.1	8
74	Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone. <i>ISRN Neurology</i> , 2013, 2013, 1-8.	1.5	8
75	More to come: Humoral immune responses in MS. <i>Journal of Neuroimmunology</i> , 2011, 240-241, 13-21.	1.1	7
76	Urine: An under-studied source of biomarkers in multiple sclerosis?. <i>Multiple Sclerosis and Related Disorders</i> , 2012, 1, 76-80.	0.9	7
77	Comparison of two commercial ELISA systems for evaluating anti-EBNA1 IgG titers. <i>Journal of Medical Virology</i> , 2013, 85, 128-131.	2.5	7
78	Predicting Multiple Sclerosis: Challenges and Opportunities. <i>Frontiers in Neurology</i> , 2021, 12, 761973.	1.1	7
79	Parkinson's Disease and Type 2 Diabetes: <scp>HbA1c</scp> Is Associated with Motor and Cognitive Severity. <i>Movement Disorders</i> , 2022, 37, 427-428.	2.2	6
80	Age-specific effects of childhood body mass index on multiple sclerosis risk. <i>Journal of Neurology</i> , 2022, 269, 5052-5060.	1.8	5
81	The shared genetic architecture of modifiable risk for Alzheimer's disease: a genomic structural equation modelling study. <i>Neurobiology of Aging</i> , 2022, 117, 222-235.	1.5	5
82	Ocrelizumab during pregnancy and lactation: Rationale and design of the MINORE and SOPRANINO studies in women with MS and their infants. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 64, 103963.	0.9	5
83	Did it hurt? COVID-19 vaccination experience in people with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 65, 104022.	0.9	5
84	A response to Cappuccio F et al.: 'Implementing a 48 h EWTD-compliant rota for junior doctors in the UK does not compromise patients' safety: assessor blind pilot comparison.'. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2009, 102, 297-298.	0.2	4
85	Risk of fractures in patients with multiple sclerosis: A population-based cohort study. <i>Neurology</i> , 2012, 79, 1934-1935.	1.5	4
86	Genome-wide association studies: will we ever predict susceptibility to multiple sclerosis through genetics?. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 235-237.	1.4	4
87	Prevalence and demographics of multiple sclerosis-associated uveitis: a UK biobank study. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 43, 102209.	0.9	4
88	UK variance in DMT advice and prescribing in MS and pregnancy: Impact of the UK consensus on pregnancy in multiple sclerosis ABN guidelines. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103272.	0.9	4
89	Brain health: The hidden casualty of a humanitarian crisis. <i>Lancet Regional Health - Europe</i> , The, 2022, 15, 100374.	3.0	4
90	OPTIMISE: MS study protocol: a pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosis. <i>BMJ Open</i> , 2021, 11, e050176.	0.8	3

#	ARTICLE	IF	CITATIONS
91	The Multiple Sclerosis Data Alliance Catalogue. International Journal of MS Care, 2021, 23, 261-268.	0.4	3
92	POI18 Increased urinary free immunoglobulin light chain excretion in patients with multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, e57-e57.	0.9	2
93	Sustained-release fampridine in Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2014, 3, 17-21.	0.9	2
94	Ethnicity and multiple sclerosis - moving beyond preconceptions. Advances in Clinical Neuroscience & Rehabilitation: ACNR, 0, 20, .	0.1	2
95	Evaluation of remote assessments for multiple sclerosis in an in-home setting. Multiple Sclerosis and Related Disorders, 2021, 54, 103125.	0.9	2
96	Breastfeeding may reduce postpartum relapse in some women with multiple sclerosis. Neurology, 2020, 94, 769-770.	1.5	2
97	Remote testing of vitamin D levels across the UK MS populationâ€”A case control study. PLoS ONE, 2020, 15, e0241459.	1.1	2
98	Social determinants of neurological disease: tackling inequalities. Lancet Neurology, The, 2022, 21, 122-123.	4.9	2
99	No evidence for association between polygenic risk of multiple sclerosis and MRI phenotypes in ~30,000 healthy adult UK Biobank participants. Multiple Sclerosis Journal, 2022, , 135245852210757.	1.4	2
100	Evaluating the feasibility of a real world pharmacovigilance study (OPTIMISE:MS). Multiple Sclerosis and Related Disorders, 2022, 63, 103894.	0.9	2
101	Peripartum disease activity in moderately and severely disabled women with multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732211049.	0.5	2
102	Achieving high standards of training. Clinical Medicine, 2009, 9, 514-514.	0.8	1
103	Digesting science: Developing educational activities about multiple sclerosis, prevention and treatment to increase the confidence of affected families. Multiple Sclerosis and Related Disorders, 2021, 47, 102624.	0.9	1
104	Perinatal Depression and Anxiety in Multiple Sclerosis. Neurology, 2021, 96, 1067-1068.	1.5	1
105	Vitamin D deficiencyâ€”do we follow our own advice?. Clinical Medicine, 2011, 11, 521-523.	0.8	0
106	158â€”Why can't I win any more?. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.114-e1.	0.9	0
107	148â€”The effect of natalizumab and interferon-Î² on urinary free light chains and anti-EBV nuclear antigen-1 antibodies in relapsing remitting multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.102-e1.	0.9	0
108	CAN WE RELIABLY USE MRI TO MONITOR TREATMENT RESPONSE IN PATIENTS ON INTERFERON Î²: A SYSTEMATIC REVIEW AND META-ANALYSIS. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, A34.3-A34.	0.9	0

#	ARTICLE	IF	CITATIONS
109	THINK OUTSIDE THE BOX, COLLAPSE THE BOX, AND TAKE A SHARP KNIFE TO IT!. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, e2.83-e2.	0.9	0
110	Bone health in multiple sclerosis: should we be doing more?. Neurodegenerative Disease Management, 2013, 3, 401-403.	1.2	0
111	Clinical commentary on "Life-threatening vitamin D intoxication due to intake of ultra-high doses in multiple sclerosis: a note of caution". Multiple Sclerosis Journal, 2019, 25, 1328-1329.	1.4	0
112	Regarding: Nicotinic acetylcholine receptors $\alpha 7$ and $\alpha 9$ modify tobacco smoke risk for multiple sclerosis. Multiple Sclerosis Journal, 2020, 27, 135245852096994.	1.4	0
113	Family planning is the second most relevant factor for treatment decisions after disease activity " Commentary. Multiple Sclerosis Journal, 2020, 26, 644-644.	1.4	0
114	Differing Impact of Disease-Modifying Therapy on Relapse and Progression. Neurology, 2021, 97, 407-408.	1.5	0
115	W26. A MULTIVARIATE GENOME-WIDE ASSOCIATION STUDY OF MODIFIABLE RISK FOR ALZHEIMER'S DISEASE: 269 LOCI ASSOCIATED WITH BRAIN HEALTH. European Neuropsychopharmacology, 2021, 51, e159.	0.3	0
116	Pregnancy in multiple sclerosis: influence on disease trajectory. Advances in Clinical Neuroscience & Rehabilitation: ACNR, 2020, 19, 15-16.	0.1	0
117	Natalizumab concentrations during pregnancy in three patients with multiple sclerosis: A clinical commentary. Multiple Sclerosis Journal, 2022, 28, 326-327.	1.4	0
118	Challenges and Opportunities of Real-World Data: Statistical Analysis Plan for the Optimise:MS Multicenter Prospective Cohort Pharmacovigilance Study. Frontiers in Neurology, 2022, 13, 799531.	1.1	0
119	Lessons From the COVID-19 Pandemic to Improve the Health, Social Care, and Well-being of Minoritized Ethnic Groups With Chronic Conditions or Impairments: Protocol for a Mixed Methods Study. JMIR Research Protocols, 2022, 11, e38361.	0.5	0
120	Remote testing of vitamin D levels across the UK MS population" A case control study. , 2020, 15, e0241459.		0
121	Remote testing of vitamin D levels across the UK MS population" A case control study. , 2020, 15, e0241459.		0
122	Remote testing of vitamin D levels across the UK MS population" A case control study. , 2020, 15, e0241459.		0
123	Remote testing of vitamin D levels across the UK MS population" A case control study. , 2020, 15, e0241459.		0
124	Lower lymphocyte count is associated with increased risk of Parkinson" s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A94.3-A95.	0.9	0
125	Ethnic and socioeconomic determinants of dementia risk: a nested case-control study in East London. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A8.2-A8.	0.9	0
126	120" ... The impact of socioeconomic status and comorbidities on emergency admissions in patients with multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A138.3-A138.	0.9	0

#	ARTICLE	IF	CITATIONS
127	Parkinson's disease determinants, prediction and gene-environment interactions: a UK Biobank study. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A7.3-A8.	0.9	0